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ABSTRACT
Recently, interferon-induced transmembrane proteins (IFITMs) have been identified to be key effector molecules in the host
type I interferon defense system. The invasion of host cells by a large range of RNA viruses is inhibited by IFITMs during the en-
try step. However, the roles of IFITMs in DNA virus infections have not been studied in detail. In this study, we report that hu-
man cytomegalovirus (HCMV), a large human DNA virus, exploits IFITMs to facilitate the formation of the virion assembly
compartment (vAC) during infection of human fibroblasts. We found that IFITMs were expressed constitutively in human em-
bryonic lung fibroblasts (MRC5 cells). HCMV infection inhibited IFITM protein accumulation in the later stages of infection.
Overexpression of an IFITM protein inMRC5 cells slightly enhanced HCMV production and knockdown of IFITMs by RNA
interference reduced the virus titer by about 100-fold on day 8 postinfection, according to the findings of a virus yield assay at a
lowmultiplicity of infection. Virus gene expression and DNA synthesis were not affected, but the typical round structure of the
vAC was not formed after the suppression of IFITMs, thereby resulting in defective virion assembly and the production of less
infectious virion particles. Interestingly, the replication of herpes simplex virus, a human herpesvirus that is closely related to
HCMV, was not affected by the suppression of IFITMs inMRC5 cells. These results indicate that IFITMs are involved in a spe-
cific pathway required for HCMV replication.
IMPORTANCE
HCMV is known to repurpose the interferon-stimulated genes (ISGs) viperin and tetherin to facilitate its replication.Our results ex-
pand the range of ISGs that can be exploited byHCMV for its replication. This is also the first report of a proviral function of IFITMs in
DNAvirus replication. In addition, whereas previous studies showed that IFITMsmodulate virus entry, which is a very early stage in
the virus life cycle, we identified a new function of IFITMsduring the very late stage of virus replication, i.e., virion assembly. Virus
entry and assembly both involve vesicle transport andmembrane fusion; thus, a commonbiochemical activity of IFITMs is likely to be
involved. Therefore, our findingsmay provide a newplatform for dissecting themolecularmechanismof action of IFITMsduring the
blocking or enhancement of virus infection, which are under intense investigation in this field.
Human cytomegalovirus (HCMV), a ubiquitous opportunisticpathogen that belongs to the Betaherpesviridae subfamily, is a
major cause of morbidity and mortality in immunocompromised
individuals (1). HCMV infection induces the expression of type I
interferon and a set of interferon (IFN)-stimulated genes (ISGs)
early upon infection (2, 3). However, HCMV encodes multiple
proteins, including IE1 (4–6), IE2 (7–9), pp65 (10, 11), and TRS1
and IRS1 (12, 13), to antagonize the innate immune responses.
Moreover, several IFN-induced host restriction factors are repur-
posed by HCMV to facilitate its replication. Viperin is relocated
from the endoplasmic reticulum to the mitochondria by vMIA,
where it enhances HCMV replication by modulating cellular lipid
metabolism (14). The antiviral protein BST2/tetherin has also
been shown to promote the entry of HCMV in BST2-overexpress-
ing cells (15). Thus, HCMV has developed mechanisms for com-
bating the host antiviral response but also to exploit antiviral mol-
ecules for its own benefit.
Recently, interferon-induced transmembrane proteins (IFITMs)
have been identified to be antiviral restriction factors that inhibit
the replication of influenza A virus and flaviviruses, including
West Nile virus and dengue virus (16). IFITMs belong to a family
of small ISGs. They contain a conserved CD225 domain, which is
related to their antiviral activity (17, 18). The broad-spectrum
antiviral activity of IFITMs has been elucidated, and it has been
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reported that IFITMs are able to restrict infections by severe acute
respiratory syndrome coronavirus, filoviruses, HIV-1, bunyavi-
ruses, reoviruses, vesicular stomatitis virus (VSV), and hepatitis C
virus (HCV) (19–24).
The majority of the viruses restricted by IFITMs are enveloped
RNA viruses whose entry is mediated through clathrin-mediated
endocytosis (18). However, the precise mechanism that allows
IFITMs to inhibit virus replication remains elusive. It has been
hypothesized that IFITMs may interfere with a membrane fusion
step of virus entry either at the cell surface or in the endosome/
lysosome compartments. This is supported by the subcellular lo-
calization of IFITMs. While IFITM1 is primarily located on the
cell surface, IFITM2 and IFITM3 are mainly present in late endo-
somes and lysosomes (25). In addition, IFITMs have been shown
to function in stabilization of v-ATPase complexes in intracellular
membranes and thus facilitate the proper subcellular localization
of clathrin (26). Recently, IFITM3 has been reported to contain an
endocytic signal which is essential for its antiviral activity. IFITM3
is likely to interact with the 2 subunit of the AP-2 complex
through which IFITM3 undergoes endocytosis (27). Finally, post-
translational modifications also play an important role in regulat-
ing the function of IFITMs (28–31).
Despite their relatively broad spectrum of antiviral activities,
IFITMs do not restrict lymphocytic choriomeningitis virus (LCMV),
Lassa virus (LASV), Machupo virus (MACV), or murine leukemia
virus (MLV) (20). It has also been reported that cells infected by DNA
viruses, such as herpes simplex virus and cytomegalovirus, can induce
the expression of ISGs, including IFITMs (32, 33). However, the role
of IFITMs in the life cycles of DNA viruses is largely unknown. A
recent study reports that IFITM protein overexpression fails to in-
hibit the entry of three DNA viruses, including HCMV (34), but de-
tailed mechanistic investigations have not been performed. In the
present study, we found that IFITMs fail to inhibit HCMV replication
in human fibroblasts, and they are actually required for the correct
formation of the virion assembly compartment (vAC) and virion
particle assembly.
HCMV profoundly reorganizes the cellular secretory apparatus to
facilitate virus assembly and egress during the later stage of its life
cycle. This event is mediated by dynamic interactions among large
numbers of viral and host proteins (35–44). The vAC assembles at a
vesicular structure, which is formed around the microtubule organi-
zation center in juxtaposition to the concave side of the nucleus,
where the vesicles with endosomal markers occupy the central posi-
tion and the vesicles with the Golgi apparatus marker are wrapped
around it to form a circle (42, 45, 46). The HCMV vAC is a unique
structure, even among the members of the herpesvirus family (35,
47). The viral nucleocapsids are formed inside the nucleus and then
bud through the two layers of the nuclear membrane. During this
process, viral nucleocapsids undergo primary envelopment and de-
envelopment. Subsequently, the naked nucleocapsids are thought to
migrate through the vAC adjacent to the nuclear membrane, where
they acquire the tegument proteins and complete their secondary
envelopment by budding into the vesicles in the vAC. We found that
IFITMs are required for the correct formation of the vAC and virion
assembly. In cells where IFITMs were suppressed by RNA interfer-
ence (RNAi), the Golgi stacks failed to rearrange into a typical circular
structure that wrapped around the vAC, the virus structure proteins
pp28, pp150, and gB failed to concentrate in the vAC, and the secreted
virion particles were less infectious. Our findings expand the range of
ISGs that can be exploited by HCMV for its own benefit.
MATERIALS AND METHODS
Plasmids and reagents. Plasmid pIPFLAG2-IFITM3, containing hu-
man IFITM3 cDNA, was constructed as described previously (30). A
Flag tag-coding sequence was introduced into the IFITM3 cDNA at the
5= end by PCR amplification. The DNA fragment was then cloned into
pLKO.DCMV.TetO, a pLKO-based lentiviral vector under the control
of a tetracycline-inducible CMV-TetO2 promoter (48), to generate
pLKO-Flag-IFITM3. To create a short hairpin RNA (shRNA)-resistant
IFITM3 expression construct, mismatch mutations in the IFITM-tar-
geting shRNA sh8025 target sequence were introduced into IFITM3
cDNA by overlapping PCR with primer pair 5=-ACGCGTCGACCAT
GGACTACAAGGACGACGATGACAAGATGAATCACACTGT
CCAAACCTTC-3= and 5=-GACTTCACGGAATAAGCGAAAGCTATAA
AGCCCAGGCAGCAGG-3= and primer pair 5=-CCTGCTGCCTGGGCTT
TATAGCTTTCGCTTATTCCGTGAAGTC-3= and 5=-GGAATTCCTATC
CATAGGCCTGGAAGATC-3=. The shRNA-resistant IFITM3 cDNA frag-
ment was then cloned into plasmid pLKO.DCMV.TetO. Two IFITM-target-
ing shRNA (sh8024 or sh8025)-expressing lentiviral vectors were constructed
on the basis of the pLKO.1 vector. The shRNA targeting sequences were as
follows: 5=-CAACAAGATGAAGAGCACCAA-3= (control shRNA [shC]),
5=-CCTCATGACCATTCTGCTCAT-3= (sh8024), and 5=-GCTTCATAGCA
TTCGCCTACT-3= (sh8025).
The primary antibodies used in this study included anti-tubulin (Pro-
teintech), anti-IFITM1 (mouse monoclonal antibody; Proteintech), anti-
IFITM2/3 (mouse monoclonal antibody; Proteintech), anti-GM130 (Cell
Signaling), anti-Flag (Abmart), anti-immediate early (anti-IE) protein
IE1/2 (a generous gift from Jay Nelson, Oregon Health & Science Univer-
sity), and anti-pp28 and anti-UL38 (gifts from Thomas Shenk, Princeton
University).
Viruses and cell lines. Human embryonic lung fibroblasts (MRC5
cells) and HEK-293T cells were maintained in Dulbecco modified Eagle
medium supplemented with 10% fetal bovine serum (FBS). To generate
cells that stably express Flag-tagged IFITM3, HEK-293T cells were trans-
fected with the recombinant pLKO-Flag-IFITM3 plasmid together with
the packaging plasmids expressing 9.2R and VSV glycoprotein G to pro-
duce the lentivirus stocks. Then, 80% confluent MRC-5 cells were trans-
duced with lentivirus supplemented with 5 g/ml Polybrene and selected
with 2 g/ml puromycin (Sigma-Aldrich).
Two bacterial artificial chromosome clones containing HCMV (pAD-
GFP and pAD/Cre) were used in the present study to produce wild-type
virus. pAD/Cre carries the whole genome of HCMV lab strain AD169.
pAD-GFP is derived from pAD/Cre, but the viral US4-US6 region is re-
placed by the green fluorescent protein (GFP) gene under the control of a
simian virus 40 (SV40) early promoter (49, 50). Herpes simplex virus 1
(HSV-1; ATCC VR1493) was a generous gift from Chiyu Zhang at the
Pathogen Diagnostic Center, Institut Pasteur of Shanghai.
shRNAknockdown.To knock down IFITMs in MRC5 cells, subconflu-
ent cells were transduced with lentiviruses encoding the shRNAs indicated
above supplemented with 5g/ml Polybrene. Cells were then incubated for 5
h at 37°C, washed with phosphate-buffered saline (PBS), and added to fresh
medium. At 24 h posttransfection, cells were either mock infected with me-
dium alone or infected with HCMV at the multiplicities of infection (MOIs)
indicated below. At 48 h posttransfection, cell lysates were collected for West-
ern blotting to detect the knockdown efficiencies of the shRNAs.
Virus growth analysis. Cells in which IFITM was overexpressed or
knocked down were seeded in 12-well dishes overnight to produce a sub-
confluent monolayer. The cells were incubated with HCMV for 1 h at an
MOI of 0.3 or 3, as indicated below. The inoculum was removed, the
monolayer was rinsed with PBS, and fresh medium was replenished. At
various times postinfection (p.i.), cell-free media from infected cultures
were collected, and the virus titers in the media were determined by a 50%
tissue culture infective dose (TCID50) assay in MRC5 cells.
Western blotting. Proteins were analyzed by Western blotting as de-
scribed previously (50). Briefly, cells were washed with phosphate-buff-
ered saline, lysed in sodium dodecyl sulfate (SDS) sample buffer supple-
Xie et al.
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mented with a protease inhibitor cocktail, and then scraped and collected
by centrifugation. Cell lysates containing equal cell numbers were re-
solved by electrophoresis on sodium dodecyl sulfate-containing poly-
acrylamide gels, subsequently transferred to polyvinylidene difluoride
membranes, hybridized with primary antibodies, and reacted with the
horseradish peroxidase-conjugated secondary antibodies. The mem-
branes were then treated with enhanced chemiluminescence (ECL) re-
agents (Bio-Rad). Finally, the protein bands were imaged by exposure to
X-ray films (Kodak).
Immunofluorescence microscopy. Cells grown on glass coverslips
were fixed in 2% paraformaldehyde (in phosphate-buffered saline) for 20
min at room temperature and permeabilized with 0.1% Triton X-100 (in
phosphate-buffered saline) for 15 min at room temperature. Subse-
quently, the cells were blocked with 5% FBS (in phosphate-buffered sa-
line) for 20 min and incubated with the primary antibodies indicated
below for 60 min at room temperature. Primary antibodies to the follow-
ing (and their dilutions) were used: IFITM1 (1:200, mouse), IFITM2/3
(1:200, mouse), GM130 (1:100, rabbit), and pp28 (1:200, mouse). Cells
were then washed with phosphate-buffered saline and stained with either
Alexa Fluor 488-conjugated secondary antirabbit antibody (1:1,000; In-
vitrogen-Molecular Probes) or Alexa Fluor 555-conjugated secondary an-
timouse antibody (1:1,000; Invitrogen-Molecular Probes). To visualize
the nuclei, cells were counterstained with DAPI (4=,6-diamidino-2-phe-
nylindole; 1:5,000; Beyotime) for 10 min. Finally, labeled cells were
mounted on slides with Prolong Gold antifade reagent (Invitrogen-Mo-
lecular Probes) overnight. Images were captured using a Leica TCS SP5
confocal laser scanning microscope.
Analysis of DNA and RNA. The intracellular DNA levels of infected
cells were examined by real-time PCR as previously described (50). MRC5
cells were infected with wild-type virus at a multiplicity of infection of 0.3,
collected at the times postinfection indicated below, resuspended in lysis
buffer (10 mM Tris-HCl [pH 8.0], 200 mM NaCl, 50 mM EDTA, 50
g/ml proteinase K, 1% SDS), and then lysed by incubation at 55°C over-
night. Total DNAs were then extracted with phenol-chloroform, treated
with 100 g/ml RNase A, extracted once more with phenol-chloroform,
precipitated with ethanol, and finally, resuspended in water. For quanti-
fying virion DNA, virus in the cultured medium was partially purified and
concentrated by ultracentrifugation on a 20% D-sorbitol cushion at
64,000 g for 1 h and then resuspended in PBS. Ten microliters of con-
centrated virus was treated with DNase I (30 U; Promega) at 37°C for 30
min to remove residual DNA that was not protected by the virus particle
and then treated at 75°C for 20 min to inactivate the DNase I. The samples
were then incubated at 55°C overnight in lysis buffer (400 mM NaCl, 10
mM Tris [pH 8.0], 10 mM EDTA, 0.1 mg of proteinase K/ml, 0.2% SDS)
TABLE 1 Primers for qPCR











HCMV IE F TCTGCCAGGACATCTTTCTCG
R GGAGACCCGCTGTTTCCAG
a F, forward; R, reverse.
FIG1 HCMV infection suppresses IFITM gene expression. (A) MRC5 cells were mock infected or infected with HCMV at an MOI of 3, and the cell lysates were collected
at the indicated times after infection. The protein levels of IFITM1 and IFITM2/3 were analyzed by immunoblotting. Commercially available antibodies recognize both
IFITM2 and IFITM3 due to the high sequence similarities of the two proteins. Viral proteins IE1/2 were used to indicate HCMV infection, and tubulin was used as the
loading control. (B) IFITM gene transcription was reduced by HCMV infection. MRC5 cells were mock infected or infected with HCMV at an MOI of 3. Total RNA was
collected at the indicated times after infection. The mRNA levels of the IFITM genes were quantified by reverse transcription-qPCR. The relative gene expression level was
normalized against that of GAPDH, and the normalized gene expression in mock-infected cells at 8 h was set equal to 1. (C) MRC5 cells were infected with HCMV (virus),
UV-inactivated virus (virusUV), or HCMV with ganciclovir (virusGCV) at an MOI of 3 or mock infected (mock). Cell lysates were collected at 48 h after infection.
(Left) The protein levels of IFITM1 and IFITM2/3 were analyzed by immunoblotting. Viral proteins IE1/2 and pp28 were used to indicate the effect of UV inactivation
and GCV treatment on virus gene expression, and tubulin was used as the loading control. (Right) A longer exposure of anti-IFITM1.
IFITMs Facilitate HCMV Virion Assembly
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and extracted with phenol-chloroform. The aqueous phase were collected
and treated with 20 g of RNase A/ml for 1 h at 37°C and then extracted
again with phenol-chloroform. The virion DNA in the aqueous phase was
precipitated with ethanol and resuspended in water. Viral DNAs and cel-
lular DNAs were quantified with SYBR Premix Ex Taq (TaKaRa) and
primers specific for the HCMV IE gene and human-actin gene (Table 1).
The accumulation of viral DNAs was normalized by dividing the number
of IE gene equivalents by the number of -actin gene equivalents.
Transcript accumulation was quantified by reverse transcription cou-
pled to real-time PCR, as previously described (51). Briefly, total RNAs
were extracted with the TRIzol reagent (Invitrogen) and reverse tran-
scribed using a PrimeScript RT reagent kit (TaKaRa). The cDNAs were
then quantified with SYBR Premix Ex Taq (TaKaRa) and with primers
specific for the cellular genes IFITM1, IFITM2, IFITM3, and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) (Table 1).
Electron microscopy. shRNA-expressing lentivirus-transduced cells
were infected with HCMV at an MOI of 0.5. At 4 days p.i., cells on the cover-
slips were fixed with 2.5% glutaraldehyde in PBS for 1 h and postfixed with
2% aqueous OsO4 for 1.5 h. Briefly, the cell monolayers were then dehydrated
with ethanol and propylene oxide, embedded in epoxy resin, and polymer-
ized at 60°C for 48 h. Embedded cell monolayers were cut into ultrathin
sections of 70 nm and then stained with uranyl acetate for 6 min and lead
FIG 2 IFITM genes were suppressed by HCMV infection. (A) MRC5 cells were infected with HCMV (AD-GFP) at an MOI of 0.5 or mock infected. Cells were
fixed at the indicated times after infection and stained with antibodies against the HCMV IE1/2 protein and the host IFITM2/3 protein. (B) An experiment similar
to that described in the legend to panel A was performed, except that the cells were stained with IFITM1 and HCMV IE1/2 antibodies.
Xie et al.
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citrate for 4 min at room temperature. Samples were analyzed by use of an FEI
Tecnai G2 Spirit transmission electron microscope.
RESULTS
HCMV infection suppresses IFITM gene expression. In order to
study a potential role of IFITMs in HCMV infection, we first ex-
amined IFITM expression in human embryonic lung fibroblasts
(MRC5 cells) before or after HCMV infection. As shown in Fig.
1A, the IFITM1 and IFITM2/3 proteins were both expressed con-
stitutively in MRC5 cells before HCMV infection. They remained
stable up to 24 h postinfection (hpi) but were reduced significantly
at 48 hpi and became undetectable at 72 hpi, according to the
results of immunoblotting. To determine whether IFITM gene
expression was altered at the mRNA level after HCMV infection,
we performed quantitative reverse transcription-PCR. As shown
in Fig. 1B, the accumulation of the mRNAs of all three IFITM
genes was reduced after HCMV infection. The reduction was ob-
vious from 24 hpi. The mRNA levels of IFITM1 and IFITM2 re-
mained relatively constant after 24 hpi, whereas the IFITM3
mRNA level decreased continuously to less than 20% of that of the
mock-infected cells at 72 hpi.
We then tested whether viral protein expression is required to
suppress IFITM accumulation. To do this, we infected MRC5 cells
with HCMV in the presence or absence of ganciclovir (GCV) or
with UV-inactivated virus and then measured IFITM protein ac-
cumulation at 48 hpi. As shown in Fig. 1C, IFITM proteins were
dramatically increased in cells infected with UV-inactivated
HCMV. UV inactivation blocks viral protein expression, as indi-
cated by no detectable IE1/2 or pp28. Therefore, the data suggest
that HCMV binding and/or entry into MRC5 cells has the ability
to induce IFITM expression, but this effect is suppressed by viral
events or viral gene expression after entry. Ganciclovir treatment
blocks viral DNA synthesis and late gene expression, as indicated
by no pp28 protein accumulation. Under such a condition, IFITM
protein accumulation was slightly reduced compared to that with
mock infection. In contrast, HCMV infection without GCV treat-
ment greatly suppressed IFITM2/3 accumulation at this time
point. The data imply that a maximum inhibition of IFITM ex-
pression requires a late viral event or late viral protein expression.
To test whether the subcellular localization of IFITMs was
changed after HCMV infection, we examined the distribution of
IFITM proteins in MRC5 cells by confocal microscopy. As shown
in Fig. 2A, IFITM2/3 located mainly as punctate structures in the
cytoplasm before infection. HCMV infection did not change the
localization of IFITM2/3, but their protein level was gradually
reduced, as indicated by the weaker staining of IFITM2/3 in in-
fected cells (IE1/2- and GFP-positive cells) at 48 and 72 hpi. The
localization of IFITM1 before or after HCMV infection is shown
in Fig. 2B. IFITM1 was expressed at a low level in mock-infected
cells. At 24 hpi, the IFITM1 signal became stronger, probably due
to the increase in the level of IFITM1 expression with time, as
shown in Fig. 1A. IFITM1 was distributed in both the nucleus and
the cytoplasm at this time point, which is different from the pre-
FIG 3 Overexpression of IFITMs in MRC5 cells fails to inhibit HCMV replication. (A) MRC5 cells were transduced with a lentiviral vector that expressed
Flag-tagged IFITM1, IFITM2, or IFITM3 or a control (ctrl) vector, and the expression of IFITMs was analyzed at 48 h after transduction by immunoblotting using
Flag tag-specific antibody. Tubulin was used as the loading control. (B) Growth analysis of HCMV infection in control or IFITM-expressing MRC5 cells at an
MOI of 0.3. The cell-free virus in the supernatant was collected on the indicated days postinfection (dpi), and the titer was determined using a TCID50 assay. (C)
Analysis of HCMV growth in control or IFITM-expressing MRC5 cells infected at an MOI of 3. (D) HCMV infection suppressed endogenous and overexpressed
Flag-IFITM3. Control or Flag-IFITM3-expressing MRC5 cells were mock infected or infected with HCMV at an MOI of 3. Expression of IFITM3 was analyzed
at 72 hpi by immunoblotting using IFITM3- or Flag tag-specific antibodies. Both Flag-tagged IFITM3 (arrowhead) and endogenous IFITM2/3 (arrow) were
detected. (E) Overexpression of IFITMs did not affect HCMV protein expression. MRC5 cells overexpressing control or Flag-tagged IFITMs (left, IFITM1;
middle, IFITM2; right, IFITM3) were infected with HCMV at an MOI of 3. Cell lysates were collected at the indicated times after infection. The accumulation of
viral proteins with immediate early (IE1/2), early (UL38), and late (pp28) kinetics was examined by immunoblotting.
IFITMs Facilitate HCMV Virion Assembly
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viously reported early endosome and plasma membrane localiza-
tion of IFITM1 (25). We had confirmed the specificity of the IF-
ITM1 antibody by staining cells expressing shRNA targeting
IFITM1 (data not shown); thus, the immunofluorescence staining
reflected the real IFITM1 localization in the cell type used in this
study. At 48 hpi and particularly at 72 hpi, the reduction of the
IFITM1 signal in HCMV-infected cells became apparent, indicat-
ing the suppression of IFITM1 expression by HCMV, which is
consistent with the immunoblotting result presented in Fig. 1A.
Overall, our data indicate that the IFITM genes were constitutively
expressed at the basal level in MRC5 cells and they were sup-
pressed rather than induced after HCMV infection.
IFITM overexpression fails to inhibit HCMV replication in
human fibroblasts. As the antiviral function of IFITMs has been
well documented, we reasoned that the significant reduction of
IFITMs at later times after HCMV infection might represent a
viral mechanism to escape from the inhibitory effect of these an-
tiviral molecules. If this is the case, we would expect the inhibition
of HCMV replication with the stable expression of IFITMs in the
host cells. To test this hypothesis, we compared virus growth at
both a high and a low multiplicity of infection (MOI) in MRC5
cells stably expressing Flag-tagged human IFITM1, IFITM2, or
IFITM3 proteins and control MRC5 cells, which were transduced
with an empty lentiviral vector (Fig. 3A). Unexpectedly, when we
measured virus growth, we did not observe any inhibition of
HCMV replication by IFITM overexpression; instead, virus pro-
duction was enhanced slightly by about 3- to 5-fold in IFITM-
expressing cells compared with that in the control cells at later
time points (Fig. 3B and C). We also checked viral protein expres-
sion. As shown in Fig. 3E, during infection, viral immediate early
protein (IE1/2), early protein (UL38), and late protein (pp28)
were almost identically expressed in control or IFITM-overex-
pressing cells. These results indicate that IFITMs are not restric-
tion factors for HCMV infection in human fibroblasts.
We noticed a reduction of Flag-tagged IFITM protein expres-
sion at a late time of infection (Fig. 3E), reminiscent of the sup-
pression of endogenous IFITMs. We compared Flag-tagged and
endogenous IFITM3 expression during HCMV infection as an
example (Fig. 3D). The Flag-tagged IFITM3 protein was expressed
at a much higher level than the endogenous IFITM2/3 before
HCMV infection (Fig. 3D). Interestingly, HCMV infection dra-
matically suppressed the expression of both endogenous and Flag-
tagged IFITMs at 72 hpi. The endogenous level became undetect-
able, and the level of Flag-tagged IFITM3 after infection was
approximately equivalent to the endogenous level before infection
(Fig. 3D). The transcription of the Flag-tagged IFITMs was driven
by an exogenous promoter that differed from the promoter driv-
ing endogenous transcription; thus, we consider that it is highly
likely that HCMV infection can inhibit IFITM protein expression
at both the transcriptional and posttranscriptional levels, which
might suppress IFITM mRNA nuclear export, attenuate transla-
tion, or induce protein degradation.
Knockdown of IFITMs by RNAi suppresses HCMV replica-
tion but not HSV replication. Although the difference was subtle,
we repeatedly observed enhanced HCMV growth after the stable ex-
pression of IFITM3 in MRC5 cells compared with the growth de-
tected in control MRC5 cells. These findings prompted us to examine
whether the endogenous IFITMs are required for HCMV replication.
FIG 4 shRNA knockdown of IFITMs inhibits HCMV replication. (A) Knockdown efficiency of shRNAs targeting IFITM genes. Cells were transduced with
lentivirus vectors expressing shC, sh8024, or sh8025. Cell lysates were collected at 48 h postransduction, and the protein levels of IFITM2/3 or IFITM1 were
examined by immunoblotting. (B) Growth analysis of HCMV infection in cells expressing shC, sh8024, or sh8025. The cells were infected at an MOI of 0.3, the
cell-free virus in the supernatant was collected at the indicated times after infection, and the titer was determined using a TCID50 assay. (C) Growth analysis of
HCMV infection in cells expressing shC, sh8024, or sh8025 at an MOI of 3. The experimental procedures were similar to those described in the legend to panel
B. (D) An independent experiment similar to that described in the legend to panel B, except the results were analyzed at more time points. (E) Downregulation
of IFITM gene expression did not inhibit HSV replication. MRC5 cells were transduced with lentivirus overexpressing shC, sh8024, or sh8025 and then infected
with HSV at an MOI of 0.01 or 0.001. The supernatant was collected at the indicated times postinfection, and titers were determined by a TCID50 assay. (F)
Downregulation of IFITM gene expression did not induce elevated cell death. MRC5 cells were transduced with shC, sh8024, or sh8025 and then stained with
propidium iodide (PI) and Hoechst at 3, 4, or 5 days after transduction. Hoechst stains the nucleus of all cells, and PI stains only dying cells with a permeable
membrane. Cells treated with PBS for 5 h were included as a positive control for cell death.
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To test this hypothesis, we used two different shRNA constructs to
knock down IFITM protein expression. As shown in Fig. 4A, con-
struct sh8024 knocked down IFITM2/3 expression almost com-
pletely in MRC5 cells, but IFITM1 expression remained intact. Con-
struct sh8025 suppressed the expression of all three IFITMs. During
measurements of virus growth, we observed reduced virus replication
in both sh8024- and sh8025-expressing cells compared with that in
the control shRNA-expressing cells (Fig. 4B and C). In a virus yield
assay (Fig. 4B), the virus titer was reduced by more than 100-fold in
sh8025-expressing cells and by about 10-fold in sh8024-expressing
cells at 8 days p.i. A growth curve at an MOI of 0.3 with more frequent
sampling is shown in Fig. 4D. Virus growth was continuously sup-
pressed up to 10 days p.i. after IFITM depletion. We noted that the
impairment of HCMV growth was much lower in the sh8024-ex-
pressing cells than the sh8025-expressing cells. This may have oc-
curred because IFITM1 was not targeted by sh8024 and the func-
tional redundancy among IFITMs is well-known (18, 20, 22).
Nevertheless, we used two different IFITM-targeting shRNA se-
quences to knock down IFITMs to demonstrate their requirement for
efficient HCMV replication. As our findings revealed a novel proviral
role of IFITMs in HCMV replication, we wanted to determine
whether it was also required for replication of a closely related her-
pesvirus. To do this, we compared the growth of herpes simplex virus
(HSV) in control cells and cells in which IFITM was knocked down.
As shown in Fig. 4E, HSV grew equivalently in cells expressing control
shRNA and shRNA targeting IFITMs, indicating a selective inhibi-
tion of HCMV replication by knocking down IFITM proteins in
MRC5 cells. Indeed, propidium iodide (PI) staining of the cells at up
to 5 days after shRNA knockdown did not detect a significant differ-
ence in cell death between the control cells and cells in which IFITM
was knocked down (Fig. 4F), thereby indicating that cell viability was
not affected by IFITM suppression.
IFITM protein downregulation minimally affects HCMV
gene expression or DNA synthesis but reduces virus infectivity.
In order to determine how IFITMs facilitate HCMV replication,
we first analyzed virus gene expression at the protein level by im-
munoblotting. As shown in Fig. 5A, the levels of immediate early
(IE1/2), early (UL38), and late (pp28) virus proteins that accumu-
lated were almost identical in the control cells and cells in which
IFITM was knocked down, thereby indicating that virus gene ex-
pression was not affected. Next, we measured virus DNA replica-
tion by quantitative PCR (qPCR) and observed that the kinetics of
virus DNA synthesis were similar in both cell types (Fig. 5B).
These data suggest that IFITMs are involved in a very late step of
the virus life cycle, i.e., after viral DNA synthesis and late protein
accumulation, which could involve virus assembly and/or egress.
To test if virus assembly or egress was affected by IFITM deple-
tion, we went on to measure the infectivity of progeny virus, rep-
resented by the ratio of the infectious unit to the number of ge-
nome copies of the secreted virus stock. Since one virus particle
contains one viral genome, the number of genome copies equals
the number of DNA-containing virus particles. A defect in virus
assembly would reduce the infectivity, whereas a defect in egress
would reduce the yield of viral particles but not the infectivity. We
infected control or sh8025-expressing cells at an MOI of 0.3, and
we then concentrated and purified the viruses secreted in the cul-
ture supernatant at 4 days p.i. Each virus stock was divided into
two to measure the number of infectious units by a TCID50 assay
and the genome copy number by qPCR. As shown in Fig. 5C, the
number of virus particles, which were represented as genome copy
numbers, was reduced slightly in sh8025-expressing cells com-
pared with the number in the control shRNA-expressing cells, but
the number of infectious units was reduced much more, by about
10-fold, at 4 days p.i., thereby leading to an approximately 5-fold
reduction in the ratio of the number of infectious units relative to
the number of genome copies. Thus, the virion particles formed in
cells in which IFITM was knocked down were about 5-fold less
infectious than those formed in control cells, thereby implying
that there was a defect in virus assembly.
IFITMs are required for the proper formation of the vAC.
HCMV virion assembly occurs at a virus-induced perinucleus
structure called the vAC, which is formed via the reorganization of
the Golgi apparatus and endosomal membrane structures. As vi-
rion assembly is likely affected by IFITM depletion, we went on to
ask whether the formation of the vAC was defective in the absence
of IFITM proteins. As shown in Fig. 6A, the Golgi stacks, which
were indicated by the Golgi apparatus marker GM130, formed
FIG 5 Suppression of IFITM gene expression has a minimal effect on viral gene
expression or DNA synthesis but significantly reduces the infectivity of the prog-
eny virus particles. (A) Knockdown of IFITM gene expression by sh8025 had little
effect on HCMV protein expression. MRC5 cells transduced with shC or sh8025
were infected with HCMV at an MOI of 3. Cell lysates were collected at the indi-
cated times after infection. The accumulation of viral proteins with immediate
early (IE1/2), early (UL38), and late (pp28) kinetics was examined by immuno-
blotting. (B) Knockdown of IFITM gene expression had a minimal effect on viral
DNA synthesis. MRC5 cells transduced with shC or sh8025 were infected with
HCMV at an MOI of 0.3. Intracellular DNA was extracted at the indicated times
after infection. The accumulation of viral DNA was quantified by qPCR, and the
amount was normalized against that of actin. The result for the DNA sample from
shC-transduced cells collected at 2 h was set equal to 1. (C) Suppression of IFITM
gene expression significantly reduced the infectivity of the progeny virus. shC- or
sh8025-expressing cells were infected by HCMV at an MOI of 0.3. The cell-free
virus in the culture medium was collected at 4 days p.i., concentrated, and purified
by use of a sorbitol cushion. Each virus stock was divided into two to measure the
infectious units by a TCID50 assay (top) and the genome copy number by qPCR
(middle). (Bottom) The ratio of the TCID50 results relative to the DNA copy
numbers was calculated for each sample. The ratio of the TCID50 results relative to
the DNA copy number for the progeny virus produced in shC-expressing cells was
set equal to 1.
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typical circular structures in cells that expressed the control
shRNA. They formed a ring-like structure that wrapped around
the vAC, where the virion structure protein pp28 was concen-
trated. In contrast, the Golgi stacks failed to form a ring-like struc-
ture in both the sh8024- and sh8025-expressing cells, and pp28
was diffused throughout the cytoplasm, thereby indicating that
the vAC did not form correctly when IFITM protein expression
was suppressed. The defect in the proper formation of vAC in the
absence of IFITMs was statistically significant (Fig. 6B). To rule
out the possibility that the defect was caused by a slower spread of the
virus in IFITM-depleted cells after the first round of infection, we
quantified vAC maturation at 3 days p.i. (Fig. 6C and D). This al-
lowed us to measure the phenotype within the first round of infec-
tion. As shown in Fig. 6D, the percentage of regular vAC was still
significantly less in cells in which IFITM was knocked down than in
the control cells at 3 days p.i. The localization of two other virus
glycoproteins, gB and pp150, was also examined at 3 days p.i. As
shown in Fig. 6E, while these two proteins were concentrated in the
vAC in control cells, they were relatively diffused throughout the cy-
toplasm after IFITM suppression. Importantly, expression of an
FIG 6 IFITMs are required for correct vAC formation. (A) MRC5 cells transduced with shC-, sh8024-, or sh8025-expressing lentiviruses were infected with
HCMV (AD/Cre) at an MOI of 0.5. Cells were fixed at 96 h postinfection and stained with antibodies against virus structural protein pp28 and the Golgi apparatus
marker GM130, both of which are proteins known to be localized to the vAC. DAPI was used to stain the nuclei. (B) Cells from the assay whose results are
presented in panel A were counted for the presence of regular vAC and irregular vAC. A typical or regular vAC is characterized by a well-formed circular Golgi
apparatus ring which is usually partially surrounded by kidney-like nuclei and a round pp28-positive structure. Irregular vAC displays a malformation of the
circular Golgi apparatus ring and a scattered pp28 distribution. Statistical significance was measured with SPSS (version 20) software (SPSS Inc.) using the
chi-square test. n, number of infected cells counted; ***, P 0.002. (C) MRC5 cells transduced with shC- or sh8025-expressing lentiviruses were infected with
HCMV (AD/Cre) at an MOI of 0.5. Cells were fixed at 72 h postinfection and stained with antibodies against virus structural protein pp28 and the Golgi apparatus
marker GM130. DAPI was used to stain the nuclei. (D) Cells from the assay whose results are presented in panel C were counted for the presence of regular vAC
and irregular vAC. n, number of infected cells counted; ***, P 0.002. (E) MRC5 cells transduced with shC- or sh8025-expressing lentiviruses were infected with
HCMV (AD/Cre) at an MOI of 0.5. Cells were fixed at 72 h postinfection and stained with antibodies against virus protein pp150 (left) or gB (right) and the Golgi
apparatus marker GM130. DAPI was used to stain the nuclei.
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shRNA-resistant IFITM3 almost completely restored the correct for-
mation of the vAC (Fig. 7A and B), further supporting the role of
IFITMs in facilitating vAC formation during HCMV infection.
Ultrastructural analysis by electron microscopy revealed a
defect in virion assembly after IFITM suppression. We went on
to examine the effect of IFITM suppression on HCMV virion as-
sembly by electron microscopy. Capsid formation in the nucleus
did not seem to be affected by IFITM knockdown (Fig. 8A). All
three forms of nuclear capsids could be detected in the presence or
absence of IFITMs, the numbers of A and C capsids were compa-
rable, and the numbers of B capsids were actually increased after
IFITM knockdown (Fig. 8B). In contrast, the defect in the forma-
tion of vAC and the secondary envelopment of the virion in the
cytoplasm were apparent. As shown in Fig. 9, the circular vAC
formed clearly at the perinuclear position in the control shRNA-
expressing cells (Fig. 9A and C). Different forms of virus particles,
including DNA-containing infectious particles, noninfectious en-
veloped particles (NIEPs) with empty capsids, and dense bodies,
were found inside the membranous vesicles (Fig. 9D and E),
thereby suggesting successful secondary envelopment. In con-
trast, the tight circular vAC structure found in the control shRNA-
expressing cells was not obvious in IFITM shRNA-expressing cells
(Fig. 9B and F), and some Golgi stacks were not reorganized (Fig.
9G, arrow), while the virus particles could be found in a gener-
FIG7 Overexpression of IFITM3 rescues vAC formation. (A) Control cells or shRNA-resistant IFITM3-expressing cells (sh8025-RE) were transduced with shC-
or sh8025-expressing lentiviruses and then infected with HCMV (AD/Cre) at an MOI of 0.5. Cells were fixed at 72 h postinfection and stained with antibodies
against virus structural protein pp28 and the Golgi apparatus marker GM130, both of which are proteins known to be localized to the vAC. DAPI was used to stain
the nuclei. (B) Cells from the assay whose results are presented in panel A were counted for the presence of regular vAC and irregular vAC. Statistical significance
was measured with SPSS (version 20) software (SPSS Inc.) using the chi-square test. n, number of infected cells counted; ns, no significant difference; ***, P
0.002. (C) Western blotting of sh8025-resistant IFITM3 expression.
FIG8 Electron microscopy analysis of the capsid assembly and DNA packaging in the presence or absence of IFITMs. (A) MRC5 cells were transduced with shC-
or sh8025-expressing lentiviruses and then infected with HCMV (AD-GFP) at an MOI of 0.5, and cells were fixed at 96 hpi and prepared for electron microscopy.
A capsids (white arrow), B capsids (white arrowhead), and C capsids (white arrowhead with a black border) are indicated. A capsids are devoid of viral DNA and
a scaffold and presumably result from abortive virus DNA packaging events. B capsids contain a scaffold but lack viral DNA. C capsids contain the viral DNA and
are devoid of a scaffold; thus, they likely represent the mature form of nucleocapsids. (B) Quantification of the different capsid types observed in the presence or
absence of IFITMs (as average values per frame). The numbers of capsids counted were 187 for shC and 271 for sh8025.
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ally diffused area of the cytoplasm (Fig. 9F), but most of the
particles were not encapsulated by a membrane structure (Fig.
9G and H). Quantitative analysis of the phenotype confirmed
that the defect in virion envelopment was statistically signifi-
cant (Fig. 9I). These data clearly indicate that there was a defect
in the formation of the vAC and a defect during the virus as-
sembly process.
DISCUSSION
IFITMs belong to a family of small ISGs that impede the cyto-
solic entry of a range of pathogenic viruses. In the present
study, however, we were surprised to find a proviral function of
IFITMs in HCMV infection. IFITMs were expressed constitu-
tively in human embryonic lung fibroblasts. The suppression
of IFITM protein expression by RNAi selectively inhibited
HCMV replication but not infection by the closely related hu-
man simplex virus. Our detailed characterization of the virus
life cycle showed that IFITMs are required for the correct for-
mation of the vAC. Thus, virus secondary envelopment was
impaired in the absence of IFITMs, whereas virus gene expres-
sion and DNA synthesis were affected only marginally. The
known function of IFITMs in virus infection is related to virus
FIG 9 Electron microscopy analysis of vAC formation and virion assembly reveals a defect in both processes after IFITM downregulation. shC- or sh8025-
expressing MRC5 cells were infected with HCMV at an MOI of 0.5, and cells were fixed and stained at 96 hpi. Electron microscopic images of shC-expressing (A)
and sh8025-expressing (B) cells infected with HCMV are shown to highlight the morphology of the nucleus (Nuc) and the vAC (circled). The white arrowhead
with a black border points to the virion particles in the vAC. (C to E) Images of another infected control shRNA-expressing cell are shown at increasing
magnifications to highlight vAC formation and virion assembly. The area in the square box in panel C is shown at a higher magnification in panel D, and the area
in the square box in panel D is shown at a further increased magnification in panel E. Different forms of virion particles and dense bodies in panels D and E are
indicated with arrows of different styles. (F to H) Images of another infected sh8025-expressing cell are shown at increasing magnifications. The areas in the
square boxes labeled G and H in panel F are shown at higher magnifications in panels G and H, respectively. Arrow in panel G, the Golgi stacks; arrow in panel
H, incompletely assembled virion particles without envelopment. (I) Quantification of HCMV secondary envelopment in the presence or absence of IFITMs.
Enveloped virions are fully formed virions that contain DNA and envelope. Nonenveloped virions include naked particles and budding particles (virion particles
attached to membranes). Statistical significance was measured using the chi-square test. n, number of virion particles counted; ***, P 0.002.
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entry, which is a very early step of the virus life cycle. IFITMs
block the entry of a range of RNA viruses into their host cells
(18), but the detailed mechanism has remained elusive, al-
though it probably occurs via inhibition of the membrane fu-
sion step of virus entry. A recent study found that IFITMs
promote infection by human coronavirus OC43, where this
particular virus utilizes the IFITMs as an entry factor (52).
However, our findings are novel because we showed that
IFITMs facilitate the replication of a large DNA virus at a very
late stage of the viral life cycle.
One counterintuitive result of this study is that HCMV infec-
tion drastically suppresses IFITM protein accumulation at the late
stage of virus infection (Fig. 1A), regardless of the role of IFITMs
in late events of the virus life cycle. How can a host protein pro-
mote a late viral event while the protein level is inhibited by virus
infection? It is possible that the presence of the IFITMs during the
early phase of virus infection primes the cellular environment for
a late viral event. This could be tested in the future by depleting
IFITMs at late times of the virus life cycle. Alternatively, immuno-
blotting might not be sufficiently sensitive to detect the trace
amounts of IFITMs that remain during the late stages of infection.
These trace amounts of IFITMs may contribute to their role in
correct vAC formation. The virus-mediated inhibition of IFITMs
does not seem to play a role in in vitro infection of HCMV in
human fibroblasts, since the stable expression of IFITMs does not
suppress HCMV replication (Fig. 3B and C). However, we cannot
rule out the possibility that it may play a functional role in certain
aspects of HCMV biology or pathology. HCMV has a broad cell
tropism in vivo, leading to pathogenesis in multiple organs of im-
munocompromised patients (53). Other virus infection systems
or latency models will be required to fully understand the inter-
play between IFITMs and HCMV infection.
How can IFITMs promote the formation of the vAC to enhance
HCMV replication? First, IFITM3 may promote vAC maturation
and HCMV production by increasing intracellular cholesterol accu-
mulation. A recent study has shown that IFITM3 disrupts intracellu-
lar cholesterol homeostasis by interfering with the interaction be-
tween vesicle-associated membrane protein (VAMP)-associated
protein A (VAPA) and oxysterol-binding protein (OSBP). Overex-
pression of IFITMs induces a marked accumulation of choles-
terol in the cells (25). Interestingly, HCMV infection is known
to use multiple mechanisms to increase intracellular choles-
terol accumulation (54–56), which is required for highly infec-
tious virion particle production (55). Second, the formation
of the HCMV vAC involves a drastic reorganization of intra-
cellular organelles, which likely requires highly regulated vesi-
cle budding, trafficking, and tethering events. A recent study
reported that a set of HCMV microRNAs attenuates the expres-
sion of host secretory pathway genes, including vesicle-associ-
ated membrane protein 3 (VAMP3), to facilitate vAC forma-
tion (57). VAPA and OSBP are known to mediate lipid transfer
and membrane tethering in different intracellular organelles
(58, 59). IFITMs could play a role in these processes by inter-
acting with VAPA and therefore promote vAC formation. Fi-
nally, IFITMs have been shown to function in stabilization of
v-ATPase complexes in intracellular membranes and thus fa-
cilitate the proper subcellular localization of clathrin (26), and
v-ATPase- and clathrin-mediated vesicle transport are likely
involved in vAC maturation (60, 61).
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